|Date:||Saturday, June 29, 2013|
|Location:||Commonwealth Hall, The Boston Seaport Hotel|
|Title:||Phase 1 clinical trial of IMO-8400, an antagonist of Toll-like receptors 7, 8 and 9|
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a weak on high relative volume candidate